Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
While the pharmaceutical industry overall has faced huge challenges in drug R&D in recent years, some major companies have consistently been much more productive than average. Here, we highlight 'organizational effectiveness' as a key factor underlying this superior performance and explain how it can be enhanced.
The search for better immunotherapy biomarkers is forcing the field to reconsider how it classifies cancers, with implications for the next wave of combination studies.
Key emerging therapies for HIV include novel combination regimens as well as extended-duration antiretroviral drugs. This article provides an overview of novel drugs and combinations in the pipeline, as well as an analysis of the current HIV drug market.
This article discusses evolving preclinical strategies for detecting drug-induced cardiotoxicity using human ion-channel assays, human-basedin silicoreconstructions and human stem cell-derived cardiomyocytes. Such strategies have the potential to improve the early detection of genuine cardiotoxicity risks, reducing the likelihood of mistakenly discarding viable drug candidates and speeding worthy drugs into clinical trials.
Metabolomics is rapidly emerging as an important tool in understanding disease mechanisms and identifying novel therapeutic strategies. Here, Wishart explores recent developments in metabolomics technologies, focusing on the growing role of metabolomics in drug discovery and its potential effect on precision medicine.
Advances in the understanding of the genetic and environmental causes of schizophrenia, and their relationship to aberrant patterns of neurodevelopment, have led to growing interest in the possibility that 'disease-modifying' strategies could alter the course to — and of — this debilitating disorder, rather than just alleviating its symptoms. This article provides a broad-based consideration of the challenges and opportunities inherent in such efforts.